GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Evolent Health Inc (NYSE:EVH) » Definitions » Beneish M-Score

Evolent Health (Evolent Health) Beneish M-Score : -2.10 (As of May. 05, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Evolent Health Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.1 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Evolent Health's Beneish M-Score or its related term are showing as below:

EVH' s Beneish M-Score Range Over the Past 10 Years
Min: -2.78   Med: -2.16   Max: -1.49
Current: -2.1

During the past 11 years, the highest Beneish M-Score of Evolent Health was -1.49. The lowest was -2.78. And the median was -2.16.


Evolent Health Beneish M-Score Historical Data

The historical data trend for Evolent Health's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolent Health Beneish M-Score Chart

Evolent Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.22 -2.40 -2.78 -1.49 -2.10

Evolent Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.49 -1.73 -0.95 -1.81 -2.10

Competitive Comparison of Evolent Health's Beneish M-Score

For the Health Information Services subindustry, Evolent Health's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolent Health's Beneish M-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Evolent Health's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Evolent Health's Beneish M-Score falls into.



Evolent Health Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Evolent Health for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2076+0.528 * 0.9987+0.404 * 1.0751+0.892 * 1.4526+0.115 * 0.5698
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9156+4.679 * -0.045973-0.327 * 0.9837
=-2.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $447 Mil.
Revenue was 556.055 + 511.015 + 469.136 + 427.69 = $1,964 Mil.
Gross Profit was 101.627 + 124.43 + 117.198 + 117.215 = $460 Mil.
Total Current Assets was $684 Mil.
Total Assets was $2,680 Mil.
Property, Plant and Equipment(Net PPE) was $90 Mil.
Depreciation, Depletion and Amortization(DDA) was $123 Mil.
Selling, General, & Admin. Expense(SGA) was $358 Mil.
Total Current Liabilities was $674 Mil.
Long-Term Debt & Capital Lease Obligation was $635 Mil.
Net Income was -33.411 + -25.324 + -34.323 + -19.982 = $-113 Mil.
Non Operating Income was -28.947 + -12.79 + -16.114 + -74.55 = $-132 Mil.
Cash Flow from Operations was 89.381 + 60.521 + 0.654 + -7.974 = $143 Mil.
Total Receivables was $255 Mil.
Revenue was 382.432 + 352.585 + 319.939 + 297.057 = $1,352 Mil.
Gross Profit was 83.064 + 85.968 + 70.234 + 77.318 = $317 Mil.
Total Current Assets was $478 Mil.
Total Assets was $1,817 Mil.
Property, Plant and Equipment(Net PPE) was $137 Mil.
Depreciation, Depletion and Amortization(DDA) was $67 Mil.
Selling, General, & Admin. Expense(SGA) was $269 Mil.
Total Current Liabilities was $433 Mil.
Long-Term Debt & Capital Lease Obligation was $469 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(446.749 / 1963.896) / (254.684 / 1352.013)
=0.227481 / 0.188374
=1.2076

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(316.584 / 1352.013) / (460.47 / 1963.896)
=0.234158 / 0.234468
=0.9987

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (683.673 + 90.177) / 2680.308) / (1 - (478.054 + 136.901) / 1817.293)
=0.711283 / 0.661609
=1.0751

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1963.896 / 1352.013
=1.4526

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(67.195 / (67.195 + 136.901)) / (123.415 / (123.415 + 90.177))
=0.329232 / 0.577807
=0.5698

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(358.11 / 1963.896) / (269.269 / 1352.013)
=0.182347 / 0.199162
=0.9156

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((635.058 + 674.242) / 2680.308) / ((468.996 + 433.442) / 1817.293)
=0.488489 / 0.496584
=0.9837

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-113.04 - -132.401 - 142.582) / 2680.308
=-0.045973

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Evolent Health has a M-score of -2.10 suggests that the company is unlikely to be a manipulator.


Evolent Health Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Evolent Health's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Evolent Health (Evolent Health) Business Description

Traded in Other Exchanges
Address
800 N. Glebe Road, Suite 500, Arlington, VA, USA, 22203
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. The company's two reportable segments: EHS and Clinical Solutions. The Company's EHS segment provides an integrated administrative and clinical platform for health plan administration and value-based business infrastructure and clinical Solutions segment addresses a broad spectrum of clinical needs, with tailored solutions for specialty care management in oncology and cardiology and increasingly the musculoskeletal markets and holistic total cost of care improvement. It generates a majority of its revenue from Clinical Solutions segment.
Executives
Seth Blackley officer: President 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Daniel Joseph Mccarthy officer: PRESIDENT 800 N GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Emily Ann Rafferty officer: Chief Operating Officer 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Toyin Ajayi director 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Cheryl Scott director 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Mary Bridget Duffy director C/O VOCERA COMMUNICATIONS, INC., 525 RACE STREET, SAN JOSE CA 95126
Diane Holder director 800 GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Richard M Jelinek director 40 W 47TH STREET, FLOOR 33, NEW YORK NY 10035
Frank J Williams director, officer: Chief Executive Officer 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
John Paul Johnson officer: Chief Financial Officer 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Jonathan Weinberg officer: General Counsel 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Steve Tutewohl officer: Chief Operating Officer 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Tunde Sotunde director 800 N. GLEBE RD, SUITE 500, ARLINGTON VA 22203
Kim Keck director 30 W. MONROE STREET, SUITE 1200, CHICAGO IL 60603
Craig A. Barbarosh director 3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305